Bitcoin, Ethereum Move Lower; Pepe Becomes Top Loser

Bitcoin (CRYPTO: BTC) moved lower, but the cryptocurrency prices remained above the $26,000 level on Friday. Ethereum (CRYPTO: ETH), also recorded losses, but traded above the key $1,600 mark this morning.

Bitcoin (CRYPTO: BTC) moved lower, but the cryptocurrency prices remained above the $26,000 level on Friday.

Ethereum (CRYPTO: ETH), also recorded losses, but traded above the key $1,600 mark this morning.

Bone ShibaSwap (CRYPTO: PEPE) turned out to be the biggest loser.

At the time of writing, the global crypto market cap fell to $1.05 trillion, recording a 24-hour decline of 1%. BTC was trading lower by 1.1% at $26,124 while ETH fell by around 0.7% to $1,655 on Friday.

Here are the top ten crypto gainers and losers over the past 24 hours:

Gainers

Bone ShibaSwap (CRYPTO: BONE)
Price: $1.44
24-hour gain: 4.5%

Mantle (CRYPTO: MNT)
Price: $0.429
24-hour gain: 1.7%

Toncoin (CRYPTO: TON)
Price: $1.43
24-hour gain: 1.1%

Monero (CRYPTO: XMR)
Price: $139.13
24-hour gain: 0.5%

TrueUSD (CRYPTO: TUSD)
Price: $0.9999
24-hour gain: 0.1%

Losers

Pepe (CRYPTO: PEPE)
Price: $0.0000008857
24-hour drop: 18.5%

Maker (CRYPTO: MKR)
Price: $1,002.70
24-hour drop: 7.9%

Conflux (CRYPTO: CFX)
Price: $0.1203
24-hour drop: 7.2%

KuCoin Token (CRYPTO: KCS)
Price: $4.52
24-hour drop: 6.9%

Sui (CRYPTO: SUI)
Price: $0.547
24-hour drop: 6.7%

Read This Next: Top 5 Real Estate Stocks That May Explode In August

Total
0
Shares
Related Posts
Read More

Organigram Reports 16% YoY Revenue Drop But Kicks Off Year ‘With A Bang,’ Says CEO On Hundreds Of Millions In Tobacco Giant BAT Investment

Canadian cannabis producer Organigram reported a 16% decrease in net revenue for Q1 2024 due to a reduction in international revenue and medical sales. The company announced in November that it had received a CA$124.6m ($93m) strategic equity investment from BT DE Investments, a subsidiary of tobacco company British American Tobacco. Organigram shareholders approved the investment in January, and the company completed the first tranche of the investment for $41.5m. CEO Beena Goldenberg said the investment had removed a significant amount of risk from Organigram's business and enhanced its competitive advantages. The investment allows the cannabis producer to utilize its facilities, research and development capabilities, and market leadership to expand its reach within the Canadian market and beyond. Organigram's Q1 financial highlights included a drop in gross margin, an increase in selling and administrative expenses, a net loss of CA$15.8m, and positive adjusted EBITDA of CA$135,000.

BTI